Synthetic Biologics (SYN) Upgraded at Zacks Investment Research  Paula Ricardo | Aug 17th, 2018
Zacks Investment Research upgraded shares of Synthetic Biologics (NYSEAMERICAN:SYN) from a hold rating to a buy rating in a research note released on Tuesday morning. They currently have $0.25 target price on the stock.
According to Zacks, "Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. " Get Synthetic Biologics alerts:
A number of other equities analysts have also weighed in on SYN. Griffin Securities lowered shares of Synthetic Biologics from a buy rating to a hold rating in a report on Wednesday, May 9th. HC Wainwright restated a buy rating on shares of Synthetic Biologics in a report on Friday, May 18th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $17.63.
Shares of SYN opened at $2.55 on Tuesday. Synthetic Biologics has a 52 week low of $2.45 and a 52 week high of $36.75.
Synthetic Biologics (NYSEAMERICAN:SYN) last issued its quarterly earnings results on Wednesday, August 8th. The company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.40) by $0.35.
A hedge fund recently raised its stake in Synthetic Biologics stock. Blair William & Co. IL raised its stake in shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 14.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,980,857 shares of the company's stock after buying an additional 255,096 shares during the period. Blair William & Co. IL owned about 1.54% of Synthetic Biologics worth $631,000 as of its most recent SEC filing.
About Synthetic Biologics
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Get a free copy of the Zacks research report on Synthetic Biologics (SYN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Synthetic Biologics Synthetic Biologic